• Home
  • Opinion
  • Politics
  • World
  • Business
  • Science & Tech
Wednesday, March 22, 2023
No Result
View All Result
SUBSCRIBE
The Outlooker
27 °c
Delhi
  • Home
  • Opinion
  • Politics
  • World
  • Business
  • Science & Tech
  • Home
  • Opinion
  • Politics
  • World
  • Business
  • Science & Tech
No Result
View All Result
The Outlooker
No Result
View All Result
  • National
  • Politics
  • Opinion
  • Business
  • Science
  • World
  • Health
Home Business

Analyst corner: Retain buy on Biocon with revised target price of Rs 480

by The Outlooker Web Desk
March 17, 2021
in Business
0
Analyst corner: Retain buy on Biocon with revised target price of Rs 480
1.8k
SHARES
12.9k
VIEWS
Share on FacebookShare on Twitter

After setbacks in Biocon Biologics/BB (top management rejig, withdrawal of biosimilars sales guidance of $1bn by FY22 etc), Biocon is pushing the reboot button.

By HSBC Global Research

US market is seeing better adoption of biosimilars, thus revalidating growth opportunities for players like Biocon. Better execution and refreshed strategies for focus markets should help Biocon in pick-up of biosimilars sales. Retain buy with revised TP of Rs 480 (from Rs 455); key catalyst – strong market share gain for launched biosimilars.

US market sees improving uptake of biosimilars: After a slow start, the US market is seeing better traction for biosimilars. Since the first biosimilar approval in 2015, the FDA has approved 29 biosimilars to date of which 20 were launched in the market (this doesn’t include three launched “follow-on-biologics” insulin products). We observe the following notable points for biosimilars in the US from recent sales and prescriptions trends: volume share for recent monoclonal antibodies (mAb) biosimilars launches – trastuzumab, rituximab and bevacizumab – reached 40-60% within two years of launch, significantly higher and faster than earlier launches; the earlier market perception, that mAbs (unlike primary care products like insulins) would see relatively slower switch to biosimilars, does not hold; we infer price erosion for biologics brands is largely in the 20-50% range post entry of biosimilars; and while we do not have sufficient data yet, a specific biologics market will take anywhere from 24 to 48 months post biosimilars entry to stabilise, in our view (similar trends were observed in the EU). We assume US biosimilars market to further evolve in terms of reimbursement mechanism, thus, revalidating growth opportunities for players like Biocon.

Biocon presses reboot button: After setbacks in Biocon Biologics/BB (top management rejig, withdrawal of biosimilars sales guidance of $1bn by FY22 etc), Biocon is pushing the reboot button. It has appointed Shreehas Tambe as deputy CEO of BB, and Susheel Umesh as Chief commercial officer/CCO for emerging markets; we believe this should help it to reinvigorate strategies for biosimilars in focus markets. Currently, its biosimilar sales split is 50:50 between MoW (most of the world) markets and developed markets (DM). While it expects higher sales and growth contribution to come from DM (especially the US), we assume MoW to remain a major contributor in the near- to medium-term (recent deal for oncology biosimilars in MoW, and CCO selection corroborates same). Execution remains the most critical factor.

Retain Buy with TP of Rs 480 (from Rs 55): We remain positive on Biocon’s long-term prospects for biosimilars and we believe improved execution of launches in the US and a renewed focus for MoW markets should help it to better pick-up biosimilars sales. Market opportunities remain abundant in DM (28 products in pipeline with cumulative brand sales of ~$80b). We make 1%-7.5% changes in our FY21-23 earnings estimates per current outlook and roll forward valuations to March 2023e from December 2022e. Our revised TP is Rs 480 (from Rs 455).

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

The Outlooker is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

The Outlooker Web Desk

The Outlooker Web Desk

Next Post
India’s Daily Covid Cases Surge To 35,871, Highest Since Early December

India's Daily Covid Cases Surge To 35,871, Highest Since Early December

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Bigger National Flag Drapes Indian Mission In UK Amid Protest By Khalistani Supporters
National

Bigger National Flag Drapes Indian Mission In UK Amid Protest By Khalistani Supporters

March 22, 2023
Paper Leak Reports Hit Morale Of Madhya Pradesh Students Taking Board Exam
National

Paper Leak Reports Hit Morale Of Madhya Pradesh Students Taking Board Exam

March 22, 2023
Social media admin held for posting meme against DMK regime’s scheme; Oppn. slams move
Politics

Social media admin held for posting meme against DMK regime’s scheme; Oppn. slams move

March 22, 2023
Active Covid Cases In India Cross 7,000 After 1,134 New Infections
National

Active Covid Cases In India Cross 7,000 After 1,134 New Infections

March 22, 2023

Connect with us

No Result
View All Result

Archives

  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020

Category

  • Artistic
  • Business
  • Crypto
  • Design
  • Entertainment
  • Fashion
  • featured
  • Food
  • Gaming
  • Health
  • Human
  • Lifestyle
  • Movie
  • Music
  • National
  • Opinion
  • Politics
  • Science
  • Spaces
  • Sports
  • Tech
  • Travel
  • Uncategorized
  • World

Recent Posts

  • Bigger National Flag Drapes Indian Mission In UK Amid Protest By Khalistani Supporters
  • Paper Leak Reports Hit Morale Of Madhya Pradesh Students Taking Board Exam
  • Social media admin held for posting meme against DMK regime’s scheme; Oppn. slams move

About Us

The Outlooker

The Outlooker is your source of authentic, hand-picked news, stories, analysis from India & the World.

  • Terms Of Service
  • Privacy Policy
  • About us
  • Submit your story
  • Contact

© 2019-2021 The Outlooker. All rights reserved.

No Result
View All Result
  • Home
  • Politics
  • World
  • Business
  • Science
  • National
  • Entertainment
  • Gaming
  • Movie
  • Music
  • Sports
  • Fashion
  • Lifestyle
  • Travel
  • Tech
  • Health
  • Food

© 2019-2021 The Outlooker. All rights reserved.